Giant Cell Arteritis (GCA)
Neurology·MeSH: Giant Cell Arteritis
Prevalence
30.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| tofidence | BIOGEN INC. (BIIB) |
Frequently asked questions
How many drugs are in development for Giant Cell Arteritis (GCA)?
BioSniper tracks 1 drug in development for Giant Cell Arteritis (GCA) across 1 company.
How many clinical trials target Giant Cell Arteritis (GCA)?
There are 2 clinical trials targeting Giant Cell Arteritis (GCA) tracked by BioSniper.
What is the prevalence of Giant Cell Arteritis (GCA)?
The estimated prevalence of Giant Cell Arteritis (GCA) is approximately 30.0 per 100,000 population.
Deep-dive into Giant Cell Arteritis (GCA)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis